A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy

Study acronym: MOMENT
StatusRecruiting
PhasePhase 3
SponsorAmgen
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
Amgen
169 trials monitored
See 11 trials at risk
The primary objective of this study to evaluate the efficacy of inebilizumab on primary membranous nephropathy (PMN) disease activity as measured by complete remission in participants with PMN.
Trial Details
NCT Number NCT07851220
Lead Sponsor Amgen
Conditions
(from sponsor)		 Glomerulonephritis, Membranous
Related terms Glomerulonephritis, Membranous
Enrollment 159 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov